Callan JMB Expands Role in Biotech Platform Scale-Up with Phase 2b/3 Push
Event summary
- Callan JMB partners with DifGen Pharmaceuticals, Aveva Drug Delivery Systems, Biostax Corp, and SGP Holdings to support U.S. scale-up of the JKB-122 (Lodonal™) immune restoration platform.
- Phase 2b/3 clinical development advancement for the lead PASC program under active FDA Investigational New Drug application.
- Callan JMB provides independent oversight for manufacturing, supply chain, and regulatory compliance to ensure federal readiness.
- Platform strategy includes development across multiple indications, including AIH, MASLD, MASH, HIV, and chronic pain.
The big picture
The collaboration underscores the growing trend toward platform-based therapeutic development, integrating manufacturing and regulatory infrastructure to support multiple indications. Callan JMB's role highlights the critical need for compliant logistics and operational oversight in scaling biotech platforms for both commercial and government deployment. The strategic anomaly lies in the convergence of logistics expertise with advanced biotech development, a dynamic that could redefine operational standards in the sector.
What we're watching
- Regulatory Alignment
- How Callan JMB's oversight will ensure compliance with BARDA, DoD, and VA standards for federal deployment.
- Platform Scalability
- Whether the shared CMC framework can efficiently support multi-indication development and commercialization.
- Execution Risk
- The pace at which manufacturing scale-up and Phase 2b/3 clinical trials will progress under independent oversight.
Related topics